Nov 8, 2020 by Jason Hawthorne2020 Will Be a Year to Remember for These 3 Healthcare StocksThe future these companies envisioned is much closer than before, thanks to the accelerated development and funding the coronavirus has brought.
Nov 7, 2020 by Jason Hawthorne3 Stocks That Are Absurdly Cheap Right NowHomebuilders are notoriously cyclical, but these stocks are benefiting from multiple tailwinds and trading for ridiculous valuations if trends continue.
Nov 6, 2020 by Jason Hawthorne2 Healthcare Stocks That Could Double Your MoneyPatient investors could double their money in these two stocks that the market has temporarily cast aside.
Nov 5, 2020 by Jason Hawthorne3 Top Mid-Cap Stocks to Buy in NovemberThese three well-managed small-caps have no debt and years of profitable growth ahead of them.
Nov 5, 2020 by Jason HawthorneIs Novavax About to Achieve Warp Speed in the Coronavirus Vaccine Race?The company is making moves that signal its growth from the coronavirus vaccine is here to stay.
Nov 3, 2020 by Jason HawthorneIs Exelixis Stock a Buy?The pharmaceutical company is moving beyond its longtime reliance on a single cancer drug, but what will those changes mean for shareholders?
Nov 3, 2020 by Jason Hawthorne2020 Will Be a Year to Forget for These 3 Healthcare StocksMany of us want to forget this year, but investors in these three companies will be especially eager to put 2020 in the rearview mirror.
Nov 2, 2020 by Jason HawthorneInvestors in These 3 Stocks Are Watching the Election CloselyBeing an easy target, uncertainty, and a declining industry give these three stocks plenty to worry about.
Nov 2, 2020 by Jason Hawthorne5 Keys to Zoom's Success, In the Words of CEO Eric YuanThe company's incredible growth is part luck and part execution, but culture may be the secret ingredient that transforms this killer app into a platform business.
Nov 1, 2020 by Jason HawthorneThese 2 Under-the-Radar Stocks Could Be Key to Coronavirus Vaccine DistributionWhile vaccine makers hog the headlines, these equipment providers are critical to the global supply chain.
Nov 1, 2020 by Jason Hawthorne3 Dividend Stocks to Buy if Donald Trump Wins the ElectionThese companies have benefited from the current administration and are likely to keep investors happy in a second Trump term.
Nov 1, 2020 by Jason Hawthorne3 Dividend Stocks to Buy if Joe Biden Wins the ElectionMarkets are unpredictable, but the candidate's policies can give us insight into how industries and investors might react.
Oct 31, 2020 by Jason Hawthorne3 Unstoppable Stocks To Buy Before or After the ElectionNo matter the outcome of the upcoming election, these industry leaders are set to excel in 2021 and beyond.
Oct 31, 2020 by Jason HawthorneAs Coronavirus Cases Climb, Here's 1 Stock to Buy and 1 to AvoidNew daily records for COVID-19 cases and hospitalizations mean these stocks are probably headed in opposite directions.
Oct 31, 2020 by Jason Hawthorne5 No-Brainer Stocks to Buy if Donald Trump Wins in NovemberA second term of the Trump administration will continue many of the same policies currently benefiting these stocks.
Oct 29, 2020 by Jason Hawthorne2 Healthcare Dividend Stocks to Buy No Matter Who Wins the ElectionToo often, high-yield stocks are too good to be true. One metric in particular can help us find the most reliable dividend payers.
Oct 28, 2020 by Jason HawthorneMove Over, Regeneron! Operation Warp Speed Has a New PartnerOperation Warp Speed is reupping with this partner to prove long-lasting prevention is better than treatment.
Oct 28, 2020 by Jason HawthorneWhy Is Everyone Talking About Livongo Health Stock?Livongo's news of a mega merger with Teladoc made waves late this summer. Investors talking about the risks of the deal may have good reason to do so.
Oct 28, 2020 by Jason HawthorneShould You Buy Immunomedics Before the Gilead Sciences Acquisition Closes?The company's recent acquisition at a lofty premium looks similar to other Gilead deals. That could mean one of two things for investors.
Oct 28, 2020 by Jason HawthorneBetter Buy: Illumina vs. ExelixisThese two stocks have very different methods of generating returns.
